Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
Identifieur interne : 004281 ( Main/Exploration ); précédent : 004280; suivant : 004282Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
Auteurs : B. Escudier [France] ; M. D. Michaelson [États-Unis] ; R. J. Motzer [États-Unis] ; T. E. Hutson [États-Unis] ; J. I. Clark [États-Unis] ; H. Y. Lim [Corée du Sud] ; E. Porfiri [Royaume-Uni] ; P. Zalewski [Canada] ; G. Kannourakis [Australie] ; M. Staehler [Allemagne] ; J. Tarazi [États-Unis] ; B. Rosbrook [États-Unis] ; L. Cisar [États-Unis] ; S. Hariharan [États-Unis] ; S. Kim [États-Unis] ; B. I. Rini [États-Unis]Source :
- British journal of cancer [ 0007-0920 ] ; 2014.
Descripteurs français
- KwdFr :
- Antinéoplasiques (effets indésirables), Antinéoplasiques (usage thérapeutique), Charge tumorale, Cytokines (usage thérapeutique), Humains, Imidazoles (effets indésirables), Imidazoles (usage thérapeutique), Indazoles (effets indésirables), Indazoles (usage thérapeutique), Indoles (usage thérapeutique), Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Nicotinamide (analogues et dérivés), Nicotinamide (effets indésirables), Nicotinamide (usage thérapeutique), Néphrocarcinome (anatomopathologie), Néphrocarcinome (mortalité), Néphrocarcinome (traitement médicamenteux), Phénylurées (effets indésirables), Phénylurées (usage thérapeutique), Pyrroles (usage thérapeutique), Résultat thérapeutique, Survie sans rechute, Tumeurs du rein (anatomopathologie), Tumeurs du rein (mortalité), Tumeurs du rein (traitement médicamenteux).
- MESH :
- analogues et dérivés : Nicotinamide.
- anatomopathologie : Néphrocarcinome, Tumeurs du rein.
- effets indésirables : Antinéoplasiques, Imidazoles, Indazoles, Inhibiteurs de protéines kinases, Nicotinamide, Phénylurées.
- mortalité : Néphrocarcinome, Tumeurs du rein.
- traitement médicamenteux : Néphrocarcinome, Tumeurs du rein.
- usage thérapeutique : Antinéoplasiques, Cytokines, Imidazoles, Indazoles, Indoles, Inhibiteurs de protéines kinases, Nicotinamide, Phénylurées, Pyrroles.
- Pascal (Inist)
- Axitinib, Charge tumorale, Etude comparative, Humains, Résultat thérapeutique, Stade avancé, Sorafénib, Survie sans rechute, Traitement, Essai clinique, Hypernéphrome, Chimiothérapie, Facteur croissance endothélium vasculaire, Cancer rein, Récepteur biologique, Cancérologie, Essai clinique phase III, Anticancéreux, Antiangiogénique, Carcinome.
English descriptors
- KwdEn :
- Advanced stage, Antiangiogenic agent, Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Antineoplastic agent, Axitinib, Biological receptor, Cancerology, Carcinoma, Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (mortality), Carcinoma, Renal Cell (pathology), Chemotherapy, Clinical trial, Comparative study, Cytokines (therapeutic use), Disease-Free Survival, Grawitz tumor, Humans, Imidazoles (adverse effects), Imidazoles (therapeutic use), Indazoles (adverse effects), Indazoles (therapeutic use), Indoles (therapeutic use), Kidney Neoplasms (drug therapy), Kidney Neoplasms (mortality), Kidney Neoplasms (pathology), Kidney cancer, Niacinamide (adverse effects), Niacinamide (analogs & derivatives), Niacinamide (therapeutic use), Phase III trial, Phenylurea Compounds (adverse effects), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyrroles (therapeutic use), Sorafenib, Treatment, Treatment Outcome, Tumor Burden, Vascular endothelium growth factor.
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Imidazoles, Indazoles, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors.
- chemical , analogs & derivatives : Niacinamide.
- chemical , therapeutic use : Antineoplastic Agents, Cytokines, Imidazoles, Indazoles, Indoles, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Pyrroles.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- mortality : Carcinoma, Renal Cell, Kidney Neoplasms.
- pathology : Carcinoma, Renal Cell, Kidney Neoplasms.
- Disease-Free Survival, Humans, Treatment Outcome, Tumor Burden.
Abstract
Background: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines. Methods: In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration (< vs ≥ median), and tumour burden (baseline sum of the longest diameter < vs ≥ median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated. Results: Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy. Conclusions: AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.
Url:
Affiliations:
- Allemagne, Australie, Canada, Corée du Sud, France, Royaume-Uni, États-Unis
- Bavière, District de Haute-Bavière, Région capitale de Séoul, Île-de-France
- Munich, Séoul
- Université Louis-et-Maximilien de Munich
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000386
- to stream PascalFrancis, to step Curation: 005A76
- to stream PascalFrancis, to step Checkpoint: 000429
- to stream Main, to step Merge: 004353
- to stream Pmc, to step Corpus: 000086
- to stream Pmc, to step Curation: 000086
- to stream Pmc, to step Checkpoint: 001734
- to stream PubMed, to step Corpus: 003741
- to stream PubMed, to step Curation: 003627
- to stream PubMed, to step Checkpoint: 003627
- to stream Ncbi, to step Merge: 001A32
- to stream Ncbi, to step Curation: 001A32
- to stream Ncbi, to step Checkpoint: 001A32
- to stream Main, to step Merge: 003C30
- to stream Main, to step Curation: 004281
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institut Gustave Roussy/Medical Oncology Department</s1><s2>Villejuif 94805</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>94805</wicri:noRegion><wicri:noRegion>Institut Gustave Roussy/Medical Oncology Department</wicri:noRegion><wicri:noRegion>Institut Gustave Roussy/Medical Oncology Department</wicri:noRegion></affiliation></author><author><name sortKey="Michaelson, M D" sort="Michaelson, M D" uniqKey="Michaelson M" first="M. D." last="Michaelson">M. D. Michaelson</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Massachusetts General Hospital Cancer Center</s1><s2>Boston, MA 02114</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Boston, MA 02114</wicri:noRegion></affiliation></author><author><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R. J." last="Motzer">R. J. Motzer</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY 10021</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, NY 10021</wicri:noRegion></affiliation></author><author><name sortKey="Hutson, T E" sort="Hutson, T E" uniqKey="Hutson T" first="T. E." last="Hutson">T. E. Hutson</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Baylor-Sammons/Texas Oncology Physician's Association, Sammons Cancer Center</s1><s2>Dallas, TX 75246</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Dallas, TX 75246</wicri:noRegion></affiliation></author><author><name sortKey="Clark, J I" sort="Clark, J I" uniqKey="Clark J" first="J. I." last="Clark">J. I. Clark</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Medicine, Loyola University Chicago Cardinal Bernardin Cancer Center</s1><s2>Maywood, IL 60153</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Maywood, IL 60153</wicri:noRegion></affiliation></author><author><name sortKey="Lim, H Y" sort="Lim, H Y" uniqKey="Lim H" first="H. Y." last="Lim">H. Y. Lim</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Internal Medicine, Samsung Medical Center/Sungkyunkwan University</s1><s2>Seoul 135-710</s2><s3>KOR</s3><sZ>6 aut.</sZ></inist:fA14><country>Corée du Sud</country><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Porfiri, E" sort="Porfiri, E" uniqKey="Porfiri E" first="E." last="Porfiri">E. Porfiri</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Queen Elizabeth Hospital Birmingham</s1><s2>Birmingham B15 2WB</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Queen Elizabeth Hospital Birmingham</wicri:noRegion></affiliation></author><author><name sortKey="Zalewski, P" sort="Zalewski, P" uniqKey="Zalewski P" first="P." last="Zalewski">P. Zalewski</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Durham Regional Cancer Centre</s1><s2>Oshawa, Ontario L1G 2B9</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Durham Regional Cancer Centre</wicri:noRegion></affiliation></author><author><name sortKey="Kannourakis, G" sort="Kannourakis, G" uniqKey="Kannourakis G" first="G." last="Kannourakis">G. Kannourakis</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services</s1><s2>Ballarat, Victoria 3355</s2><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services</wicri:noRegion></affiliation></author><author><name sortKey="Staehler, M" sort="Staehler, M" uniqKey="Staehler M" first="M." last="Staehler">M. Staehler</name><affiliation wicri:level="4"><inist:fA14 i1="10"><s1>Ludwig-Maximiians University of Munich</s1><s2>Munich 80539</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Tarazi, J" sort="Tarazi, J" uniqKey="Tarazi J" first="J." last="Tarazi">J. Tarazi</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Pfizer Oncology</s1><s2>San Diego, CA 92121</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Rosbrook, B" sort="Rosbrook, B" uniqKey="Rosbrook B" first="B." last="Rosbrook">B. Rosbrook</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Pfizer Oncology</s1><s2>San Diego, CA 92121</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Cisar, L" sort="Cisar, L" uniqKey="Cisar L" first="L." last="Cisar">L. Cisar</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Pfizer Oncology</s1><s2>New York, NY 10017</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Hariharan, S" sort="Hariharan, S" uniqKey="Hariharan S" first="S." last="Hariharan">S. Hariharan</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Pfizer Oncology</s1><s2>New York, NY 10017</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Kim, S" sort="Kim, S" uniqKey="Kim S" first="S." last="Kim">S. Kim</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Pfizer Oncology</s1><s2>San Diego, CA 92121</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Rini, B I" sort="Rini, B I" uniqKey="Rini B" first="B. I." last="Rini">B. I. Rini</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute</s1><s2>Cleveland, OH 44195</s2><s3>USA</s3><sZ>16 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Cleveland, OH 44195</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0157368</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0157368 INIST</idno><idno type="RBID">Pascal:14-0157368</idno><idno type="wicri:Area/PascalFrancis/Corpus">000386</idno><idno type="wicri:Area/PascalFrancis/Curation">005A76</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000429</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000429</idno><idno type="wicri:doubleKey">0007-0920:2014:Escudier B:axitinib:versus:sorafenib</idno><idno type="wicri:Area/Main/Merge">004353</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056058</idno><idno type="RBID">PMC:4056058</idno><idno type="wicri:Area/Pmc/Corpus">000086</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000086</idno><idno type="wicri:Area/Pmc/Curation">000086</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000086</idno><idno type="wicri:Area/Pmc/Checkpoint">001734</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001734</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">003741</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003741</idno><idno type="wicri:Area/PubMed/Curation">003627</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003627</idno><idno type="wicri:Area/PubMed/Checkpoint">003627</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003627</idno><idno type="wicri:Area/Ncbi/Merge">001A32</idno><idno type="wicri:Area/Ncbi/Curation">001A32</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A32</idno><idno type="wicri:doubleKey">0007-0920:2014:Escudier B:axitinib:versus:sorafenib</idno><idno type="wicri:Area/Main/Merge">003C30</idno><idno type="wicri:Area/Main/Curation">004281</idno><idno type="wicri:Area/Main/Exploration">004281</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institut Gustave Roussy/Medical Oncology Department</s1><s2>Villejuif 94805</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Michaelson, M D" sort="Michaelson, M D" uniqKey="Michaelson M" first="M. D." last="Michaelson">M. D. Michaelson</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Massachusetts General Hospital Cancer Center</s1><s2>Boston, MA 02114</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Boston, MA 02114</wicri:noRegion></affiliation></author><author><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R. J." last="Motzer">R. J. Motzer</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY 10021</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, NY 10021</wicri:noRegion></affiliation></author><author><name sortKey="Hutson, T E" sort="Hutson, T E" uniqKey="Hutson T" first="T. E." last="Hutson">T. E. Hutson</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Baylor-Sammons/Texas Oncology Physician's Association, Sammons Cancer Center</s1><s2>Dallas, TX 75246</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Dallas, TX 75246</wicri:noRegion></affiliation></author><author><name sortKey="Clark, J I" sort="Clark, J I" uniqKey="Clark J" first="J. I." last="Clark">J. I. Clark</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Medicine, Loyola University Chicago Cardinal Bernardin Cancer Center</s1><s2>Maywood, IL 60153</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Maywood, IL 60153</wicri:noRegion></affiliation></author><author><name sortKey="Lim, H Y" sort="Lim, H Y" uniqKey="Lim H" first="H. Y." last="Lim">H. Y. Lim</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Internal Medicine, Samsung Medical Center/Sungkyunkwan University</s1><s2>Seoul 135-710</s2><s3>KOR</s3><sZ>6 aut.</sZ></inist:fA14><country>Corée du Sud</country><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Porfiri, E" sort="Porfiri, E" uniqKey="Porfiri E" first="E." last="Porfiri">E. Porfiri</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Queen Elizabeth Hospital Birmingham</s1><s2>Birmingham B15 2WB</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Queen Elizabeth Hospital Birmingham</wicri:noRegion></affiliation></author><author><name sortKey="Zalewski, P" sort="Zalewski, P" uniqKey="Zalewski P" first="P." last="Zalewski">P. Zalewski</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Durham Regional Cancer Centre</s1><s2>Oshawa, Ontario L1G 2B9</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Durham Regional Cancer Centre</wicri:noRegion></affiliation></author><author><name sortKey="Kannourakis, G" sort="Kannourakis, G" uniqKey="Kannourakis G" first="G." last="Kannourakis">G. Kannourakis</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services</s1><s2>Ballarat, Victoria 3355</s2><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services</wicri:noRegion></affiliation></author><author><name sortKey="Staehler, M" sort="Staehler, M" uniqKey="Staehler M" first="M." last="Staehler">M. Staehler</name><affiliation wicri:level="4"><inist:fA14 i1="10"><s1>Ludwig-Maximiians University of Munich</s1><s2>Munich 80539</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Tarazi, J" sort="Tarazi, J" uniqKey="Tarazi J" first="J." last="Tarazi">J. Tarazi</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Pfizer Oncology</s1><s2>San Diego, CA 92121</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Rosbrook, B" sort="Rosbrook, B" uniqKey="Rosbrook B" first="B." last="Rosbrook">B. Rosbrook</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Pfizer Oncology</s1><s2>San Diego, CA 92121</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Cisar, L" sort="Cisar, L" uniqKey="Cisar L" first="L." last="Cisar">L. Cisar</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Pfizer Oncology</s1><s2>New York, NY 10017</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Hariharan, S" sort="Hariharan, S" uniqKey="Hariharan S" first="S." last="Hariharan">S. Hariharan</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Pfizer Oncology</s1><s2>New York, NY 10017</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Kim, S" sort="Kim, S" uniqKey="Kim S" first="S." last="Kim">S. Kim</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Pfizer Oncology</s1><s2>San Diego, CA 92121</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pfizer Oncology</wicri:noRegion></affiliation></author><author><name sortKey="Rini, B I" sort="Rini, B I" uniqKey="Rini B" first="B. I." last="Rini">B. I. Rini</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute</s1><s2>Cleveland, OH 44195</s2><s3>USA</s3><sZ>16 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Cleveland, OH 44195</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">British journal of cancer</title><title level="j" type="abbreviated">Br. j. cancer</title><idno type="ISSN">0007-0920</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">British journal of cancer</title><title level="j" type="abbreviated">Br. j. cancer</title><idno type="ISSN">0007-0920</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Antiangiogenic agent</term><term>Antineoplastic Agents (adverse effects)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antineoplastic agent</term><term>Axitinib</term><term>Biological receptor</term><term>Cancerology</term><term>Carcinoma</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (mortality)</term><term>Carcinoma, Renal Cell (pathology)</term><term>Chemotherapy</term><term>Clinical trial</term><term>Comparative study</term><term>Cytokines (therapeutic use)</term><term>Disease-Free Survival</term><term>Grawitz tumor</term><term>Humans</term><term>Imidazoles (adverse effects)</term><term>Imidazoles (therapeutic use)</term><term>Indazoles (adverse effects)</term><term>Indazoles (therapeutic use)</term><term>Indoles (therapeutic use)</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (mortality)</term><term>Kidney Neoplasms (pathology)</term><term>Kidney cancer</term><term>Niacinamide (adverse effects)</term><term>Niacinamide (analogs & derivatives)</term><term>Niacinamide (therapeutic use)</term><term>Phase III trial</term><term>Phenylurea Compounds (adverse effects)</term><term>Phenylurea Compounds (therapeutic use)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrroles (therapeutic use)</term><term>Sorafenib</term><term>Treatment</term><term>Treatment Outcome</term><term>Tumor Burden</term><term>Vascular endothelium growth factor</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (effets indésirables)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Charge tumorale</term><term>Cytokines (usage thérapeutique)</term><term>Humains</term><term>Imidazoles (effets indésirables)</term><term>Imidazoles (usage thérapeutique)</term><term>Indazoles (effets indésirables)</term><term>Indazoles (usage thérapeutique)</term><term>Indoles (usage thérapeutique)</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Nicotinamide (analogues et dérivés)</term><term>Nicotinamide (effets indésirables)</term><term>Nicotinamide (usage thérapeutique)</term><term>Néphrocarcinome (anatomopathologie)</term><term>Néphrocarcinome (mortalité)</term><term>Néphrocarcinome (traitement médicamenteux)</term><term>Phénylurées (effets indésirables)</term><term>Phénylurées (usage thérapeutique)</term><term>Pyrroles (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Survie sans rechute</term><term>Tumeurs du rein (anatomopathologie)</term><term>Tumeurs du rein (mortalité)</term><term>Tumeurs du rein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Imidazoles</term><term>Indazoles</term><term>Niacinamide</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Niacinamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Cytokines</term><term>Imidazoles</term><term>Indazoles</term><term>Indoles</term><term>Niacinamide</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term><term>Pyrroles</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Nicotinamide</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term><term>Imidazoles</term><term>Indazoles</term><term>Inhibiteurs de protéines kinases</term><term>Nicotinamide</term><term>Phénylurées</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Cytokines</term><term>Imidazoles</term><term>Indazoles</term><term>Indoles</term><term>Inhibiteurs de protéines kinases</term><term>Nicotinamide</term><term>Phénylurées</term><term>Pyrroles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease-Free Survival</term><term>Humans</term><term>Treatment Outcome</term><term>Tumor Burden</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Axitinib</term><term>Charge tumorale</term><term>Etude comparative</term><term>Humains</term><term>Résultat thérapeutique</term><term>Stade avancé</term><term>Sorafénib</term><term>Survie sans rechute</term><term>Traitement</term><term>Essai clinique</term><term>Hypernéphrome</term><term>Chimiothérapie</term><term>Facteur croissance endothélium vasculaire</term><term>Cancer rein</term><term>Récepteur biologique</term><term>Cancérologie</term><term>Essai clinique phase III</term><term>Anticancéreux</term><term>Antiangiogénique</term><term>Carcinome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines. Methods: In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration (< vs ≥ median), and tumour burden (baseline sum of the longest diameter < vs ≥<sub> </sub>median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated. Results: Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy. Conclusions: AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Corée du Sud</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li><li>Région capitale de Séoul</li><li>Île-de-France</li></region><settlement><li>Munich</li><li>Séoul</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name></region></country><country name="États-Unis"><noRegion><name sortKey="Michaelson, M D" sort="Michaelson, M D" uniqKey="Michaelson M" first="M. D." last="Michaelson">M. D. Michaelson</name></noRegion><name sortKey="Cisar, L" sort="Cisar, L" uniqKey="Cisar L" first="L." last="Cisar">L. Cisar</name><name sortKey="Clark, J I" sort="Clark, J I" uniqKey="Clark J" first="J. I." last="Clark">J. I. Clark</name><name sortKey="Hariharan, S" sort="Hariharan, S" uniqKey="Hariharan S" first="S." last="Hariharan">S. Hariharan</name><name sortKey="Hutson, T E" sort="Hutson, T E" uniqKey="Hutson T" first="T. E." last="Hutson">T. E. Hutson</name><name sortKey="Kim, S" sort="Kim, S" uniqKey="Kim S" first="S." last="Kim">S. Kim</name><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R. J." last="Motzer">R. J. Motzer</name><name sortKey="Rini, B I" sort="Rini, B I" uniqKey="Rini B" first="B. I." last="Rini">B. I. Rini</name><name sortKey="Rosbrook, B" sort="Rosbrook, B" uniqKey="Rosbrook B" first="B." last="Rosbrook">B. Rosbrook</name><name sortKey="Tarazi, J" sort="Tarazi, J" uniqKey="Tarazi J" first="J." last="Tarazi">J. Tarazi</name></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Lim, H Y" sort="Lim, H Y" uniqKey="Lim H" first="H. Y." last="Lim">H. Y. Lim</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Porfiri, E" sort="Porfiri, E" uniqKey="Porfiri E" first="E." last="Porfiri">E. Porfiri</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Zalewski, P" sort="Zalewski, P" uniqKey="Zalewski P" first="P." last="Zalewski">P. Zalewski</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Kannourakis, G" sort="Kannourakis, G" uniqKey="Kannourakis G" first="G." last="Kannourakis">G. Kannourakis</name></noRegion></country><country name="Allemagne"><region name="Bavière"><name sortKey="Staehler, M" sort="Staehler, M" uniqKey="Staehler M" first="M." last="Staehler">M. Staehler</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004281 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004281 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0157368
|texte= Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
}}
| This area was generated with Dilib version V0.6.33. |  |